English
SpanishTrusted Resources: News & Meetings
Latest announcements and gatherings
Apitope Announces Positive Results With Novel Treatment for Graves’ Disease
Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases (including multiple sclerosis (MS), Graves’ disease and uveitis), today announced positive results from the Phase I first in man clinical trial of its product candidate, ATX-GD-59, in development for the treatment of Graves’ disease.
Graves’ disease is one of the most common autoimmune diseases with approximately 10 million patients across Europe and the US and yet there have been no innovative treatments in more than 60 years. With Graves’ disease, the immune system mistakenly attacks the thyroid gland and causes it to become overactive. Symptoms can include an enlargement of the thyroid gland, swelling of the neck, localised abnormalities of skin, tremors, heat intolerance and sweating, significant weight loss, osteoporosis, atrial fibrillation and ocular changes in patients. Each year 20-30 out of every 100,000 people are newly diagnosed with Graves’ disease.
myBinderRelated Content
-
American Thyroid Association® Satellite Symposium: Personalized Approach to Thyroid DisordersUpdate: The American Thyroid Association...
-
Columbia Thyroid CenterColumbia Thyroid Center helps to treat t...
-
The University of Kansas Medical CenterThe Head and Neck Surgery Team in the De...
-
Thyroid Disorders and OsteoporosisWhat is Osteoporosis? Osteoporosis - li...
-
Treatment of Hyperthyroidism With Antithyroid Drugs Corrects Mild Neutropenia in Graves’ DiseaseContext: Neutropenia secondary to antit...
-
Radioiodine Therapy for HyperthyroidismA 37-year-old woman receives a diagnosis...
-
Prevention of Overt Hypothyroidism Following Radioactive Iodine Therapy for Graves’ Disease By Early Initiatio...Background: Radioactive iodine (RAI) th...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Brought to you by
Supported through an independent
educational grant by
